Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
Niagen Bioscience formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and